现代仪器与医疗
現代儀器與醫療
현대의기여의료
Modern Instruments & Mediccal Treatment
2015年
5期
4-7
,共4页
辛伐他汀%剂量%冠状动脉粥样硬化%血管内皮细胞
辛伐他汀%劑量%冠狀動脈粥樣硬化%血管內皮細胞
신벌타정%제량%관상동맥죽양경화%혈관내피세포
Simvastatin%Dose%Coronary atherosclerosis%Vascular endothelial cells
目的:分析不同剂量辛伐他汀对冠状动脉粥样硬化症患者血管内皮细胞功能影响,探讨其作用机制。方法:选取我院2010年6月~2014年6月收治的528例冠状动脉粥样硬化症患者,按照其低密度脂蛋白胆固醇(LDL-C)水平分为 A 组(LDL-C ≥4.16 mmol/L)、B 组(3.64 mmol/L ≤ LDL-C <4.16 mmol/L)、C 组(2.60 mmol/L ≤ LDL-C <3.64 mmol/L)及 D 组(LDL-C <2.60 mmol/L),使用不同剂量辛伐他汀进行治疗。观察其治疗前后血管内皮功能变化。结果:治疗前 A、B、C 三组患者 TC、LDL-C 水平显著高于 D 组(P <0.05),各组 TG、HDL-C、血清 NO 水平比较无明显统计学差异(P >0.05)。治疗后 A、B、C 三组患者 TC、LDL-C 水平显著降低,血清 NO 水平显著升高(P <0.05),其 TC、LDL-C 水平与 D 组患者比较无明显统计学差异(P >0.05)。治疗前后各组患者肱动脉基础内经、NMD 均未见明显改变(P >0.05),治疗后 A、B、C 三组患者 FMD 均显著升高(P <0.05),D 组患者 FMD 未见明显改变(P >0.05)。结论:针对冠状动脉粥样硬化症患者血清 LDL-C 水平选择合适剂量的辛伐他汀有助于提升其血清 NO 水平,改善血管内皮细胞功能。
目的:分析不同劑量辛伐他汀對冠狀動脈粥樣硬化癥患者血管內皮細胞功能影響,探討其作用機製。方法:選取我院2010年6月~2014年6月收治的528例冠狀動脈粥樣硬化癥患者,按照其低密度脂蛋白膽固醇(LDL-C)水平分為 A 組(LDL-C ≥4.16 mmol/L)、B 組(3.64 mmol/L ≤ LDL-C <4.16 mmol/L)、C 組(2.60 mmol/L ≤ LDL-C <3.64 mmol/L)及 D 組(LDL-C <2.60 mmol/L),使用不同劑量辛伐他汀進行治療。觀察其治療前後血管內皮功能變化。結果:治療前 A、B、C 三組患者 TC、LDL-C 水平顯著高于 D 組(P <0.05),各組 TG、HDL-C、血清 NO 水平比較無明顯統計學差異(P >0.05)。治療後 A、B、C 三組患者 TC、LDL-C 水平顯著降低,血清 NO 水平顯著升高(P <0.05),其 TC、LDL-C 水平與 D 組患者比較無明顯統計學差異(P >0.05)。治療前後各組患者肱動脈基礎內經、NMD 均未見明顯改變(P >0.05),治療後 A、B、C 三組患者 FMD 均顯著升高(P <0.05),D 組患者 FMD 未見明顯改變(P >0.05)。結論:針對冠狀動脈粥樣硬化癥患者血清 LDL-C 水平選擇閤適劑量的辛伐他汀有助于提升其血清 NO 水平,改善血管內皮細胞功能。
목적:분석불동제량신벌타정대관상동맥죽양경화증환자혈관내피세포공능영향,탐토기작용궤제。방법:선취아원2010년6월~2014년6월수치적528례관상동맥죽양경화증환자,안조기저밀도지단백담고순(LDL-C)수평분위 A 조(LDL-C ≥4.16 mmol/L)、B 조(3.64 mmol/L ≤ LDL-C <4.16 mmol/L)、C 조(2.60 mmol/L ≤ LDL-C <3.64 mmol/L)급 D 조(LDL-C <2.60 mmol/L),사용불동제량신벌타정진행치료。관찰기치료전후혈관내피공능변화。결과:치료전 A、B、C 삼조환자 TC、LDL-C 수평현저고우 D 조(P <0.05),각조 TG、HDL-C、혈청 NO 수평비교무명현통계학차이(P >0.05)。치료후 A、B、C 삼조환자 TC、LDL-C 수평현저강저,혈청 NO 수평현저승고(P <0.05),기 TC、LDL-C 수평여 D 조환자비교무명현통계학차이(P >0.05)。치료전후각조환자굉동맥기출내경、NMD 균미견명현개변(P >0.05),치료후 A、B、C 삼조환자 FMD 균현저승고(P <0.05),D 조환자 FMD 미견명현개변(P >0.05)。결론:침대관상동맥죽양경화증환자혈청 LDL-C 수평선택합괄제량적신벌타정유조우제승기혈청 NO 수평,개선혈관내피세포공능。
Objective: To analyze the effect of different doses of simvastatin on endothelium function in patients with coronary atherosclerosis, and to explore its mechanism of action. Methods: The 528 cases of coronary atherosclerosis patients were divided into 4 groups in according to the level of low density lipoprotein cholesterol (LDL-C) : group A (LDL-C≥4.16 mmol/L), group B (3.64 mmol/L ≤ LDL-C < 4.16 mmol/L), group C (2.60, mmol/L ≤ LDL-C < 3.64 mmol/L) and group D (LDL-C ≤ 2.60 mmol/L). All the patients were treated with different doses of simvastatin. Then observed the changes of vascular endothelial function before and after treatment of all gourps. Results: Before treatment, the TC, LDL-C levels of A, B, C groups of patients were significantly higher than that of D group (P < 0.05). After treatment, TC, LDL-C level of A, B, C groups of patients were significantly decreased, which were no significant differences with group D, and the level of serum NO was significantly increased (P < 0.05). Before and after treatment in each group, the brachial artery and NMD in patients showed no obvious change (P > 0.05). After treatment, the FMD of A, B, C groups of patients were significantly increased (P < 0.05), but D group of patients with FMD had no obvious change (P > 0.05). Conclusion: According to the serum LDL-C level in patients with coronary atherosclerosis and select the appropriate dose of simvastatin helps to enhance the serum level of NO, and to improve the function of vascular endothelial cells.